Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.146
Neutral
RSI(14)
40.634
Neutral
STOCH(KDJ)(9,3,3)
31.207
Buy
ATR(14)
1.374
Low Volatility
CCI(14)
-88.710
Neutral
Williams %R
67.304
Sell
TRIX(12,20)
-0.742
Sell
StochRSI(14)
100.000
Buy
Twist Bioscience Corp
TWST25.370USD
-0.240-0.94%
Market hours （ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
44.686
Target Price
+84.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.75% year-on-year.
Undervalued
The company’s latest PE is -16.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.44M shares, decreasing 0.43% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 6.40M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.78.
Financial Health
Currency: USD Updated：2025-09-10The company's current financial score is 7.62, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 92.79M, representing a year-over-year increase of 23.23%, while its net profit experienced a year-over-year increase of 13.55%.
Score
Financials
9.56
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
6.79
Operational Efficiency
7.46
Growth Potential
7.17
Shareholder Returns
7.09
Company Valuation
Currency: USD Updated：2025-09-10The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is -18.96, which is -65.23% below the recent high of -6.59 and 37.24% above the recent low of -11.90.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 61/177
No Data
Earnings Forecast
Currency: USD Updated：2025-09-10The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Twist Bioscience Corp is 45.00, with a high of 57.17 and a low of 35.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
11
analysts
Buy
Current Rating
44.686
Target Price
+74.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
179
Total
5
Median
8
Average
Company name
Ratings
Analysts
Twist Bioscience Corp
TWST
11
Biogen Inc
BIIB
35
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
32
Alnylam Pharmaceuticals Inc
ALNY
32
Eli Lilly and Co
LLY
31
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-10The company’s current price momentum score is 7.04, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 33.32 and the support level at 22.67, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
25.374
Sell
MA10
25.830
Sell
MA20
26.734
Sell
MA50
30.990
Sell
MA100
32.350
Sell
MA200
38.649
Sell
Institutional Confidence
Currency: USD Updated：2025-09-10The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 116.72%, representing a quarter-over-quarter decrease of 0.43%. The largest institutional shareholder is Catherine Wood, holding a total of 6.40M shares, representing 10.60% of shares outstanding, with 12.90% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Artisan Partners Limited Partnership
BlackRock Institutional Trust Company, N.A.
William Blair Investment Management, LLC
State Street Global Advisors (US)
Nikko Asset Management Co., Ltd.
Invesco Advisers, Inc.
1
2
Risk Assessment
Currency: USD Updated：2025-09-10The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.22, which is lower than the Pharmaceuticals industry's average of 3.51. The company's beta value is 2.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.39
VaR
+7.89%
240-Day Maximum Drawdown
+55.32%
240-Day Volatility
+75.45%
Return
Best Daily Return
60 days
+8.01%
120 days
+14.47%
5 years
+28.74%
Worst Daily Return
60 days
-10.30%
120 days
-10.30%
5 years
-20.05%
Sharpe Ratio
60 days
-1.61
120 days
-1.24
5 years
+0.00
Risk Assessment
Maximum Drawdown
240 days
+55.32%
3 years
+70.82%
5 years
+94.48%
Return-to-Drawdown Ratio
240 days
-0.79
3 years
-0.11
5 years
-0.16
Skewness
240 days
+0.21
3 years
+0.66
5 years
+0.30
Volatility
Realised Volatility
240 days
+75.45%
5 years
+82.83%
Standardised True Range
240 days
+9.83%
5 years
+15.90%
Downside Risk-Adjusted Return
120 days
-198.19%
240 days
-198.19%
Maximum Daily Upside Volatility
60 days
+43.43%
Maximum Daily Downside Volatility
60 days
+47.81%
Liquidity
Average Turnover Rate
60 days
+2.20%
120 days
+2.12%
5 years
--
Turnover Deviation
20 days
+78.44%
60 days
+21.90%
120 days
+17.81%
Peer Comparison
Currency: USD Updated：2025-09-10Twist Bioscience Corp
TWST
6.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
7.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BridgeBio Pharma Inc
BBIO
7.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Biogen Inc
BIIB
7.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
